Patents by Inventor Tahamtan Ahmadi

Tahamtan Ahmadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20220112301
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Brian Elliott, Tahamtan Ahmadi
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20220112287
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Brian Elliott, Jenny Jianlin CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20220112300
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W. L. CHIU, Esther C.W. BREIJ
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20210403592
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 30, 2021
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • AXL-SPECIFIC ANTIBODIES FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
    Publication number: 20210393793
    Abstract: The present invention relates to immunoconjugates anti-AXL antibodies and compositions for treatment of non-small cell lung cancer.
    Type: Application
    Filed: September 26, 2019
    Publication date: December 23, 2021
    Inventors: Esther BREIJ, Ulf FORSSMANN, Tahamtan AHMADI
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20210371538
    Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
    Type: Application
    Filed: May 7, 2021
    Publication date: December 2, 2021
    Inventors: Tahamtan AHMADI, Manish GUPTA, Tommy LI, Roberto OLIVERI, Dena DEMARCO, Ida HIEMSTRA, Christopher CHIU, Brian ELLIOTT, Ada AZARYAN
  • Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
    Patent number: 11021543
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20210070869
    Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 11, 2021
    Inventors: Maarten JANMAAT, Esther BREIJ, Ulf FORSSMANN, Tahamtan AHMADI, Julia BOSHUIZEN, Daniel PEEPER, Nora PENCHEVA
  • VARIANTS OF CD38 ANTIBODY AND USES THEREOF
    Publication number: 20200165352
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 28, 2020
    Inventors: Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • VARIANTS OF CD38 ANTIBODY AND USES THEREOF
    Publication number: 20200017600
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: July 15, 2019
    Publication date: January 16, 2020
    Inventors: Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20190144557
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: October 16, 2018
    Publication date: May 16, 2019
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • Methods of Treating High Risk Multiple Myeloma
    Publication number: 20190127479
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20170044265
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser, Niels van de Donk
  • Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
    Publication number: 20160376373
    Abstract: The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 29, 2016
    Inventors: Tahamtan Ahmadi, Tineke Casneuf, Henk Lokhorst, Tuna Mutis, Amy Sasser